Product Code: GVR-4-68040-481-1
De-identified Health Data Market Growth & Trends:
The global de-identified health data market size is expected to reach USD 13.59 billion by 2030, registering a CAGR of 9.0% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market's growth is primarily driven by the rising demand for data analytics in healthcare, which supports population health studies and predictive modeling while ensuring patient privacy. Increasing regulatory pressure surrounding data protection, combined with AI and machine learning advancements, is creating a growing need for large-scale, de-identified datasets. In addition, the surge in data from wearables and electronic health records (EHRs) generates substantial volumes of information suitable for de-identification and secondary use, further boosting market demand.
De-identified data is utilized to derive insights into insurance status by analyzing patterns related to patient enrollment in pharmacy and medical insurance. This data enables organizations to identify primary and secondary payers, assess coverage trends, and understand patient demographics without compromising privacy. For instance, in June 2024, Komodo Health introduced the Komodo Patient Insurance (KPI). This novel data offering provides detailed insights into the insurance status of over 200 million de-identified U.S. patients. This resource accurately identifies patients' pharmacy and medical insurance enrollment, detailing primary and secondary payer information across various channels, segments, and geographies. The KPI will assist Commercial, Market Access, Medical Affairs, and Health Economics and Outcomes Research (HEOR) teams in efficiently addressing key business questions related to patient enrollment and payer mapping.
Moreover, the increasing partnership and collaboration among the key market players are expected to drive market growth. For instance, in March 2024, Verantos announced a partnership with Curimeta to enhance the utilization of de-identified health data in clinical research. This collaboration focuses on improving real-world evidence generation while ensuring patient privacy through robust data de-identification processes. By leveraging Curimeta's data science capabilities and Verantos' expertise in real-world data, the partnership aims to provide valuable insights that can drive healthcare innovations and improve patient outcomes. The emphasis on de-identified data is crucial for facilitating secure data sharing and compliance with regulatory standards.
"The Verantos Evidence Platform uses artificial intelligence (AI) to generate unique disease-specific insights. It is critical that AI models are trained using high-quality patient care data. CuriMeta's participation will enable us to enhance our disease-specific Pragmatic Registries that are used to accelerate life sciences research."
Anand Shroff, President of Verantos
De-identified Health Data Market Report Highlights:
- Based on the type of data, the clinical data segment dominated the market with almost 17.0% of the share in 2023. The segment's dominance is attributed to its crucial role in research, treatment development, and patient care optimization
- Based on application, the clinical research and trials segment held the largest revenue share of 14.5% in 2023. This is attributed to its key role in advancing treatment methods, medical device innovation, and patient safety
- Based on the end use, the healthcare providers segment held the largest revenue share in 2023. The healthcare providers segment leads the market owing to its crucial role in clinical decision-making, treatment optimization, and patient outcome improvement
- North America dominated the market with a revenue share of 31.8% in 2023. The region has an advanced healthcare infrastructure and significant technological investment, particularly in data analytics and AI
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Type of data
- 1.1.2. End use
- 1.1.3. Application
- 1.1.4. Regional scope
- 1.1.5. Estimates and forecast timeline.
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database.
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.4.1. Data analysis models
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.6.1. Commodity flow analysis (Model 1)
- 1.6.2. Approach 1: Commodity flow approach
- 1.6.3. Volume price analysis (Model 2)
- 1.6.4. Approach 2: Volume price analysis
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Type of data outlook
- 2.2.2. End use outlook
- 2.2.3. Application outlook
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
Chapter 3. De-identified Health Data Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
- 3.3. De-identified Health Data Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Economic landscape
- 3.3.2.3. Social landscape
- 3.3.2.4. Technological landscape
- 3.3.2.5. Environmental landscape
- 3.3.2.6. Legal landscape
- 3.3.3. COVID-19 Impact
Chapter 4. De-identified Health Data Market: Type of Data Estimates & Trend Analysis
- 4.1. Type of Data Market Share, 2023 & 2030
- 4.2. Segment Dashboard
- 4.3. Global De-identified Health Data Market by Type of Data Outlook
- 4.4. Clinical Data
- 4.4.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 4.5. Genomic Data
- 4.5.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 4.6. Patient Demographics
- 4.6.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 4.7. Prescription Data
- 4.7.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 4.8. Claims Data
- 4.8.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 4.9. Behavioral Data
- 4.9.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 4.10. Wearable and Sensor Data
- 4.10.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 4.11. Survey and Patient-Reported Data
- 4.11.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 4.12. Imaging Data
- 4.12.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 4.13. Laboratory Data
- 4.13.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 4.14. Hospital and Provider Data
- 4.14.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 4.15. Social Determinants of Health (SDoH) Data
- 4.15.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 4.16. Pharmacogenomic Data
- 4.16.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 4.17. Biometric Data
- 4.17.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 4.18. Operational and Financial Data
- 4.18.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 4.19. Epidemiological Data
- 4.19.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 4.20. Healthcare Utilization Data
- 4.20.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 4.21. Others
- 4.21.1. Market estimates and forecast 2018 - 2030 (USD Million)
Chapter 5. De-identified Health Data Market: End Use Estimates & Trend Analysis
- 5.1. End Use Market Share, 2023 & 2030
- 5.2. Segment Dashboard
- 5.3. Global De-identified Health Data Market by Mode of Delivery Outlook
- 5.4. Pharmaceutical Companies
- 5.4.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 5.5. Biotechnology Firms
- 5.5.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 5.6. Medical Device Manufacturers
- 5.6.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 5.7. Healthcare Providers
- 5.7.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 5.8. Insurance Companies/ Healthcare Payers
- 5.8.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 5.9. Research Institutions
- 5.9.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 5.10. Government Agencies
- 5.10.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 5.11. Others
- 5.11.1. Market estimates and forecast 2018 - 2030 (USD Million)
Chapter 6. De-identified Health Data Market: Application Estimates & Trend Analysis
- 6.1. Application Market Share, 2023 & 2030
- 6.2. Segment Dashboard
- 6.3. Global De-identified Health Data Market by Application Outlook
- 6.4. Clinical Research and Trials
- 6.4.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 6.5. Public Health
- 6.5.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 6.6. Precision Medicine
- 6.6.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 6.7. Health Economics and Outcomes Research (HEOR)
- 6.7.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 6.8. Population Health Management
- 6.8.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 6.9. Drug Discovery and Development
- 6.9.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 6.10. Healthcare Quality Improvement
- 6.10.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 6.11. Insurance Underwriting and Risk Assessment
- 6.11.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 6.12. Market Access and Commercial Strategy
- 6.12.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 6.13. Business Intelligence and Operational Efficiency
- 6.13.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 6.14. Telemedicine and Remote Monitoring
- 6.14.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 6.15. Patient Engagement and Support Programs
- 6.15.1. Market estimates and forecast 2018 - 2030 (USD Million)
- 6.16. Others
- 6.16.1. Market estimates and forecast 2018 - 2030 (USD Million)
Chapter 7. De-identified Health Data Market: Regional Estimates & Trend Analysis, By Type of Data, By End use, By Application
- 7.1. Regional Market Share Analysis, 2023 & 2030
- 7.2. Regional Market Dashboard
- 7.3. Global Regional Market Snapshot
- 7.4. Market Size, & Forecasts Trend Analysis, 2018 - 2030:
- 7.5. North America
- 7.5.1. U.S.
- 7.5.1.1. Key country dynamics
- 7.5.1.2. Regulatory framework/ reimbursement structure
- 7.5.1.3. Competitive scenario
- 7.5.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
- 7.5.2. Canada
- 7.5.2.1. Key country dynamics
- 7.5.2.2. Regulatory framework/ reimbursement structure
- 7.5.2.3. Competitive scenario
- 7.5.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
- 7.5.3. Mexico
- 7.5.3.1. Key country dynamics
- 7.5.3.2. Regulatory framework/ reimbursement structure
- 7.5.3.3. Competitive scenario
- 7.5.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
- 7.6. Europe
- 7.6.1. UK
- 7.6.1.1. Key country dynamics
- 7.6.1.2. Regulatory framework/ reimbursement structure
- 7.6.1.3. Competitive scenario
- 7.6.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
- 7.6.2. Germany
- 7.6.2.1. Key country dynamics
- 7.6.2.2. Regulatory framework/ reimbursement structure
- 7.6.2.3. Competitive scenario
- 7.6.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
- 7.6.3. France
- 7.6.3.1. Key country dynamics
- 7.6.3.2. Regulatory framework/ reimbursement structure
- 7.6.3.3. Competitive scenario
- 7.6.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
- 7.6.4. Italy
- 7.6.4.1. Key country dynamics
- 7.6.4.2. Regulatory framework/ reimbursement structure
- 7.6.4.3. Competitive scenario
- 7.6.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
- 7.6.5. Spain
- 7.6.5.1. Key country dynamics
- 7.6.5.2. Regulatory framework/ reimbursement structure
- 7.6.5.3. Competitive scenario
- 7.6.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
- 7.6.6. Norway
- 7.6.6.1. Key country dynamics
- 7.6.6.2. Regulatory framework/ reimbursement structure
- 7.6.6.3. Competitive scenario
- 7.6.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
- 7.6.7. Sweden
- 7.6.7.1. Key country dynamics
- 7.6.7.2. Regulatory framework/ reimbursement structure
- 7.6.7.3. Competitive scenario
- 7.6.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
- 7.6.8. Denmark
- 7.6.8.1. Key country dynamics
- 7.6.8.2. Regulatory framework/ reimbursement structure
- 7.6.8.3. Competitive scenario
- 7.6.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
- 7.7. Asia Pacific
- 7.7.1. Japan
- 7.7.1.1. Key country dynamics
- 7.7.1.2. Regulatory framework/ reimbursement structure
- 7.7.1.3. Competitive scenario
- 7.7.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
- 7.7.2. China
- 7.7.2.1. Key country dynamics
- 7.7.2.2. Regulatory framework/ reimbursement structure
- 7.7.2.3. Competitive scenario
- 7.7.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
- 7.7.3. India
- 7.7.3.1. Key country dynamics
- 7.7.3.2. Regulatory framework/ reimbursement structure
- 7.7.3.3. Competitive scenario
- 7.7.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
- 7.7.4. Australia
- 7.7.4.1. Key country dynamics
- 7.7.4.2. Regulatory framework/ reimbursement structure
- 7.7.4.3. Competitive scenario
- 7.7.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
- 7.7.5. South Korea
- 7.7.5.1. Key country dynamics
- 7.7.5.2. Regulatory framework/ reimbursement structure
- 7.7.5.3. Competitive scenario
- 7.7.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
- 7.7.6. Thailand
- 7.7.6.1. Key country dynamics
- 7.7.6.2. Regulatory framework/ reimbursement structure
- 7.7.6.3. Competitive scenario
- 7.7.6.4. Singapore market estimates and forecasts 2018 - 2030 (USD Million)
- 7.8. Latin America
- 7.8.1. Brazil
- 7.8.1.1. Key country dynamics
- 7.8.1.2. Regulatory framework/ reimbursement structure
- 7.8.1.3. Competitive scenario
- 7.8.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
- 7.8.2. Argentina
- 7.8.2.1. Key country dynamics
- 7.8.2.2. Regulatory framework/ reimbursement structure
- 7.8.2.3. Competitive scenario
- 7.8.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
- 7.9. MEA
- 7.9.1. South Africa
- 7.9.1.1. Key country dynamics
- 7.9.1.2. Regulatory framework/ reimbursement structure
- 7.9.1.3. Competitive scenario
- 7.9.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
- 7.9.2. Saudi Arabia
- 7.9.2.1. Key country dynamics
- 7.9.2.2. Regulatory framework/ reimbursement structure
- 7.9.2.3. Competitive scenario
- 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
- 7.9.3. UAE
- 7.9.3.1. Key country dynamics
- 7.9.3.2. Regulatory framework/ reimbursement structure
- 7.9.3.3. Competitive scenario
- 7.9.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
- 7.9.4. Kuwait
- 7.9.4.1. Key country dynamics
- 7.9.4.2. Regulatory framework/ reimbursement structure
- 7.9.4.3. Competitive scenario
- 7.9.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Company/Competition Categorization
- 8.3. Innovators
- 8.4. Vendor Landscape
- 8.4.1. List of key distributors and channel partners
- 8.4.2. Key customers
- 8.4.3. Key company market share analysis, 2023
- 8.4.4. IQVIA
- 8.4.4.1. Company overview
- 8.4.4.2. Financial performance
- 8.4.4.3. Technology Type benchmarking
- 8.4.4.4. Strategic initiatives
- 8.4.5. Oracle (Cerner Corporation)
- 8.4.5.1. Company overview
- 8.4.5.2. Financial performance
- 8.4.5.3. Technology Type benchmarking
- 8.4.5.4. Strategic initiatives
- 8.4.6. Merative (Truven Health Analytics)
- 8.4.6.1. Company overview
- 8.4.6.2. Financial performance
- 8.4.6.3. Technology Type benchmarking
- 8.4.6.4. Strategic initiatives
- 8.4.7. Optum, Inc. (UnitedHealth Group)
- 8.4.7.1. Company overview
- 8.4.7.2. Financial performance
- 8.4.7.3. Technology Type benchmarking
- 8.4.7.4. Strategic initiatives
- 8.4.8. ICON plc
- 8.4.8.1. Company overview
- 8.4.8.2. Financial performance
- 8.4.8.3. Technology Type benchmarking
- 8.4.8.4. Strategic initiatives
- 8.4.9. Veradigm LLC (Formerly known as Allscripts)
- 8.4.9.1. Company overview
- 8.4.9.2. Financial performance
- 8.4.9.3. Technology Type benchmarking
- 8.4.9.4. Strategic initiatives
- 8.4.10. IBM
- 8.4.10.1. Company overview
- 8.4.10.2. Financial performance
- 8.4.10.3. Technology Type benchmarking
- 8.4.10.4. Strategic initiatives
- 8.4.11. Flatiron Health (F. Hoffmann-La Roche Ltd)
- 8.4.11.1. Company overview
- 8.4.11.2. Financial performance
- 8.4.11.3. Technology Type benchmarking
- 8.4.11.4. Strategic initiatives
- 8.4.12. Premier, Inc.
- 8.4.12.1. Company overview
- 8.4.12.2. Financial performance
- 8.4.12.3. Technology Type benchmarking
- 8.4.12.4. Strategic initiatives
- 8.4.13. Shaip
- 8.4.13.1. Company overview
- 8.4.13.2. Financial performance
- 8.4.13.3. Technology Type benchmarking
- 8.4.13.4. Strategic initiatives
- 8.4.14. Komodo Health, Inc.
- 8.4.14.1. Company overview
- 8.4.14.2. Financial performance
- 8.4.14.3. Technology Type benchmarking
- 8.4.14.4. Strategic initiatives
- 8.4.15. Evidation Health, Inc.
- 8.4.15.1. Company overview
- 8.4.15.2. Financial performance
- 8.4.15.3. Technology Type benchmarking
- 8.4.15.4. Strategic initiatives
- 8.4.16. Medidata
- 8.4.16.1. Company overview
- 8.4.16.2. Financial performance
- 8.4.16.3. Technology Type benchmarking
- 8.4.16.4. Strategic initiatives
- 8.4.17. Clarify Health Solutions
- 8.4.17.1. Company overview
- 8.4.17.2. Financial performance
- 8.4.17.3. Technology Type benchmarking
- 8.4.17.4. Strategic initiatives
- 8.4.18. Satori Cyber Ltd.
- 8.4.18.1. Company overview
- 8.4.18.2. Financial performance
- 8.4.18.3. Technology Type benchmarking
- 8.4.18.4. Strategic initiatives